BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34336664)

  • 21. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
    Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
    Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
    Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
    Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.
    Zhou B; Sun C; Hu X; Zhan H; Zou H; Feng Y; Qiu F; Zhang S; Wu L; Zhang B
    Cell Physiol Biochem; 2017; 44(5):1867-1881. PubMed ID: 29224010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury.
    Qu D; May R; Sureban SM; Weygant N; Chandrakesan P; Ali N; Li L; Barrett T; Houchen CW
    Am J Physiol Gastrointest Liver Physiol; 2014 Mar; 306(5):G404-11. PubMed ID: 24368703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KDM3A promotes oral squamous cell carcinoma cell proliferation and invasion via H3K9me2 demethylation-activated DCLK1.
    Yang L; Zhang Q; Yang Q
    Genes Genomics; 2022 Nov; 44(11):1333-1342. PubMed ID: 36094735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
    Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.
    Schinke H; Shi E; Lin Z; Quadt T; Kranz G; Zhou J; Wang H; Hess J; Heuer S; Belka C; Zitzelsberger H; Schumacher U; Genduso S; Riecken K; Gao Y; Wu Z; Reichel CA; Walz C; Canis M; Unger K; Baumeister P; Pan M; Gires O
    Mol Cancer; 2022 Sep; 21(1):178. PubMed ID: 36076232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UBE2C promotes the progression of head and neck squamous cell carcinoma.
    Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
    Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of the Wnt/β-Catenin signaling pathway in the heterogenous nuclear ribonucleoprotein K-driven inhibition of proliferation and migration in head and neck squamous cell carcinoma.
    Liu H; Chen X; Yang X; Li M; Zhang W; Zhang G; Zhan X; Cao L; Li W; Huang Z; Gao R
    Oncol Lett; 2020 Dec; 20(6):394. PubMed ID: 33193854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
    Wang J; Wang S; Zhou J; Qian Q
    Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
    Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
    Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reciprocal activation of HEY1 and NOTCH4 under SOX2 control promotes EMT in head and neck squamous cell carcinoma.
    Fukusumi T; Guo TW; Ren S; Haft S; Liu C; Sakai A; Ando M; Saito Y; Sadat S; Califano JA
    Int J Oncol; 2021 Feb; 58(2):226-237. PubMed ID: 33491747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
    Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
    Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
    Carli ALE; Afshar-Sterle S; Rai A; Fang H; O'Keefe R; Tse J; Ferguson FM; Gray NS; Ernst M; Greening DW; Buchert M
    Proteomics; 2021 Jul; 21(13-14):e2000098. PubMed ID: 33991177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch signaling drives development of Barrett's metaplasia from Dclk1-positive epithelial tuft cells in the murine gastric mucosa.
    Kunze B; Middelhoff M; Maurer HC; Agibalova T; Anand A; Bührer AM; Fang HY; Baumeister T; Steiger K; Strangmann J; Schmid RM; Wang TC; Quante M
    Sci Rep; 2021 Feb; 11(1):4509. PubMed ID: 33627749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.
    Qu D; Weygant N; Yao J; Chandrakesan P; Berry WL; May R; Pitts K; Husain S; Lightfoot S; Li M; Wang TC; An G; Clendenin C; Stanger BZ; Houchen CW
    J Oncol; 2019; 2019():6402925. PubMed ID: 31467540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
    Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.